Dermapharm Q1 revenue rises on branded pharmaceuticals growth, confirms 2026 outlook

Dermapharm Holding SE

13/05/2026 06:52

Overview

Germany-based branded pharmaceuticals maker's Q1 revenue up 1.1% yr/yr, driven by branded segment

Adjusted EBITDA for Q1 rose 7.5%, with margin improving to 28.6%

Company confirms 2026 revenue and adjusted EBITDA guidance

Outlook

Dermapharm expects 2026 consolidated revenue of EUR 1,182–1,218 mln

Company sees 2026 adjusted EBITDA at EUR 331–341 mln

Dermapharm confirms guidance for 2026 following Q1 results in line with projections

Result Drivers

BRANDED PHARMACEUTICALS GROWTH - Strong organic growth and acquisitions in the branded segment, including Mucos Group and F. Trenka, drove revenue gains

PARALLEL IMPORT DECLINE - Revenue in the Parallel import business fell as planned due to a focus on higher-margin products

ARKOPHARMA REORGANISATION - Slight revenue decline in Other healthcare products segment attributed to Arkopharma business model reorganisation

Company press release: ID:nEQ5LQ7wRa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
EUR 305.80 mln
Q1 Adjusted EBITDA
EUR 87.40 mln
Q1 Adjusted EBITDA Margin
28.60%
Q1 EBITDA
EUR 91.20 mln
Q1 EBITDA Margin
29.80%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Dermapharm Holding SE is €41.00, about 11.4% below its May 12 closing price of €46.30

The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 14 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)